ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials.
about
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyDendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-AnalysisGranzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells.Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.The functional contribution of calcium ion flux heterogeneity in T cells.Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells.Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody.Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma.Immune reactivity after adenoviral-mediated aquaporin-1 cDNA transfer to human parotid glands.Presentation of available CTL epitopes that induction of cell-mediated immune response against HIV-1 Koran clade B strain using computational technology.Immunohistochemical expression of granzyme B and perforin in discoid lupus erythematosus.Microfluidic compartments with sensing microbeads for dynamic monitoring of cytokine and exosome release from single cells.In vitro immunotherapy potency assays using real-time cell analysis.PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes.Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.
P2860
Q26745516-2A28D10C-324B-45D4-9B0D-B7C88C2FEDE5Q28070121-985AFC4F-E6E2-4550-B34B-12517527CA5DQ35269599-DF8E0A62-934C-4E0A-8F5B-074DB210D41FQ36558219-E25A6BD2-779C-4D92-A09B-80B7086E9416Q38396331-A871CF30-BC3D-4C21-8DE8-85B6830FA74FQ38759782-8B7FBBAF-8EC1-4F5B-9988-FDFA31EF3EE7Q38787705-9EFC614D-DC62-4143-AD5B-FB7AE39D9518Q38901871-29E33F30-762B-407D-8B4C-7568FCCE94D8Q39154244-3737FBFD-7F33-48AD-873A-923FF6292666Q40950213-602A372E-7ECA-4318-BA3C-EDAC04F20101Q45114686-15AF7379-7BBE-4444-BDC5-0050469C344FQ46416408-F40A8E50-71A7-4B29-BB85-006CAE75A60DQ52369403-F8D40901-CC82-4CF7-BBBB-0F2BC4593236Q52647698-30A8CF67-7E18-44A1-B341-09747DF2691EQ52806003-5CC29D7F-8535-4323-8EEA-E9D0538EB159Q55364522-F4E165C5-68F2-4AD1-99C8-8655FD4458A3
P2860
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ELISPOT Assay for Monitoring C ...... ancer Vaccine Clinical Trials.
@en
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes
@nl
type
label
ELISPOT Assay for Monitoring C ...... ancer Vaccine Clinical Trials.
@en
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes
@nl
prefLabel
ELISPOT Assay for Monitoring C ...... ancer Vaccine Clinical Trials.
@en
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes
@nl
P2093
P2860
P356
P1433
P1476
ELISPOT Assay for Monitoring C ...... ancer Vaccine Clinical Trials.
@en
P2093
Anatoli M Malyguine
Kimberly Dunham
Michael R Shurin
Susan Strobl
Thomas J Sayers
P2860
P304
P356
10.3390/CELLS1020111
P577
2012-05-10T00:00:00Z